Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

United Therapeutics Hurt By Competitive Pressure


Argus provided its outlook on United Therapeutics Corporation (NASDAQ: UTHR), mentioning the negative effects of competitive pressures and regulatory delays. The company's primary drug, treprostinil, is used to treat patients suffering from pulmonary arterial hypertension (PAH). The company has expanded its presence in the domestic PAH market with three forms of treprostinil, and has now added a pill version, Orenitram, to this franchise.

The analysts noted their concerns that Orenitram is facing increased competitive pressure from Actelion's Uptravi, despite the company's strong 2Q16 results. The company is also experiencing regulatory delays with its new subcutaneous implantable device for treprostinil, which is expected to replace the current pump system.

Moreover, Argus views the unexpected resignation of two senior executives (Co-CEO Roger Jeffs and COO David Zaccardelli) after the release of first-quarter earnings in April, as a negative sign and thus reiterates its Hold rating on shares.

Latest Ratings for UTHR

May 2019UpgradesSellNeutral
May 2019UpgradesUnderperformNeutral
May 2019MaintainsOutperformOutperform

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: ArgusAnalyst Color Reiteration Analyst Ratings


Related Articles (UTHR)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

JDA Software Chooses Blackstone Investment Over Selling Itself To Honeywell

Jefferies Sees Limited Catalysts For Madison Square Garden, Downgrades